Jun 04, 2015 7:05am EDT Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
Jun 01, 2015 8:00am EDT Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
May 26, 2015 7:35am EDT Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
Apr 07, 2015 8:05am EDT Matinas BioPharma to Present at the 2nd Annual Growth Capital Expo on April 13, 2015
Mar 04, 2015 8:05am EST Matinas BioPharma to Present at the 27th Annual ROTH Conference on March 11, 2015
Feb 05, 2015 8:05am EST Matinas BioPharma to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Jan 30, 2015 8:25am EST Matinas BioPharma Establishes Lipid-Based, Anti-Infective Platform, With Acquisition of Aquarius BioTechnologies Inc.
